Skip to content

TNGX

Tango Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$28.25-1.10%

Price as of Jul 20, 2026

TNGX ownership

Tango Therapeutics, Inc. ownership & insider activity

Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.

Insider Activity

Sentiment
0/100
Buys (3m)
0
Sells (3m)
6
Net (3m)
-$2.0M
Insider trades by month Buys Sells
Feb
Mar
Apr
May
Jun
Jul
Context3-month price +8.2%Institutions accumulating (13F)
DateInsiderTypeSharesPrice
Jul 2, 2026Crystal Adamofficer: President, R&DSell19,629$29.34
Jul 2, 2026Crystal Adamofficer: President, R&DSell7,371$30.25
Jul 2, 2026Crystal Adamofficer: President, R&DOption27,000$5.20
Jun 23, 2026Azelby RobertdirectorGrant5,740
Jun 23, 2026Azelby RobertdirectorGrant35,910$27.97
Jun 8, 2026Lee SungdirectorGrant3,570$20.22
Jun 8, 2026Ketchum John BdirectorGrant4,000
Jun 8, 2026Ketchum John BdirectorGrant25,000$20.22
Jun 8, 2026Calhoun Lesley AnndirectorGrant4,000
Jun 8, 2026Calhoun Lesley AnndirectorGrant25,000$20.22
Jun 8, 2026Rothenberg MacedirectorGrant4,000
Jun 8, 2026Rothenberg MacedirectorGrant25,000$20.22
Jun 8, 2026Lee SungdirectorGrant570
Jun 3, 2026Crystal Adamofficer: President, R&DOption27,000$5.20
Jun 3, 2026Crystal Adamofficer: President, R&DSell6,140$22.25
Jun 3, 2026Crystal Adamofficer: President, R&DSell20,860$23.06
May 5, 2026Gall Matthewofficer: Chief Financial OfficerGrant240,000$20.98
May 5, 2026Crystal Adamofficer: President, R&DSell1,100$22.00
May 5, 2026Gall Matthewofficer: Chief Financial OfficerGrant40,000
May 5, 2026Crystal Adamofficer: President, R&DOption27,000$5.20
May 5, 2026Crystal Adamofficer: President, R&DSell25,900$21.19
May 1, 2026Lee SungdirectorGrant12,300
May 1, 2026Lee SungdirectorGrant5,200$22.06
Apr 16, 2026Crystal Adamofficer: President, R&DSell38,460$25.00
Apr 16, 2026Crystal Adamofficer: President, R&DOption38,460$5.20
Apr 2, 2026Crystal Adamofficer: President, R&DSell27,000$21.20
Apr 2, 2026Crystal Adamofficer: President, R&DOption27,000$5.20
Mar 27, 2026Crystal Adamofficer: President, R&DSell12,000$20.11
Mar 27, 2026Crystal Adamofficer: President, R&DOption12,000$5.20
Mar 9, 2026Crystal Adamofficer: President, R&DSell20,251$15.00

Source: TNGX SEC Form 4 filings, latest Jul 2, 2026. For informational purposes only — not investment advice.

Institutional activity (13F)

How institutions changed their TNGX positions over the last 6 months (SEC Form 13F).

Increased
141
New positions
113
Reduced
90
Sold out
59
Largest moves
InstitutionActionSharesFiled
RTW INVESTMENTS, LPIncreased13.3MMay 15, 2026
FARALLON CAPITAL MANAGEMENT LLCIncreased13.1MFeb 17, 2026
ADAGE CAPITAL PARTNERS GP, L.L.C.Increased12.8MMay 15, 2026
TCG CROSSOVER MANAGEMENT, LLCIncreased12.8MFeb 17, 2026
BOXER CAPITAL MANAGEMENT, LLCUnchanged10.9MMay 15, 2026
BOXER CAPITAL MANAGEMENT, LLCIncreased10.9MFeb 17, 2026
FARALLON CAPITAL MANAGEMENT LLCIncreased10.8MFeb 17, 2026
ADAGE CAPITAL PARTNERS GP, L.L.C.Increased10.6MFeb 17, 2026
TCG CROSSOVER MANAGEMENT, LLCReduced10.5MMay 15, 2026
BOXER CAPITAL MANAGEMENT, LLCUnchanged10.4MFeb 17, 2026
WOODLINE PARTNERS LPIncreased10.1MFeb 17, 2026
FMR LLCIncreased9.9MMay 15, 2026
BOXER CAPITAL MANAGEMENT, LLCUnchanged9.8MFeb 17, 2026
BOXER CAPITAL MANAGEMENT, LLCReduced9.8MFeb 17, 2026
FARALLON CAPITAL MANAGEMENT LLCReduced9.1MMay 15, 2026

Source: SEC Form 13F filings. For informational purposes only — not investment advice.